N E W S B Y T E S
can have diverse mechanisms of action , offer versatile administration routes alongside high oral bioavailability , and are cheap to manufacture . As such , small molecules have enjoyed historical predominance , with approximately 80 % of all drugs being small molecules , according to GlobalData ’ s Drugs Database .
Alternatively , biologic drugs are derived from living organisms produced by cutting-edge biotechnological technologies and methods . The term biologic covers a variety of molecule types , including monoclonal antibodies and cell therapies . These therapies offer different modalities to treat diseases that were once considered impossible to target and can be used in conditions for which no other treatments are available .
Veeda engages with life sciences startups for Phase 1 trial solutions
Veeda Group in collaboration with Atal Incubation Centre – Centre for Cellular and Molecular Biology ( AIC – CCMB ) organized a half-day symposium on Phase 1 trial solutions for emerging life sciences start-up companies , at Hyderabad . The symposium , titled “ Integrated Phase I Trial Solutions for Emerging Biopharmaceuticals : Addressing Development Challenges and Accelerating Timelines ” aimed to address the challenges and optimize the processes related to the development of New Chemical Entities ( NCEs ) and Large Molecules .
The registered participants at the Phase 1 symposium featured life sciences startup companies from healthcare , biopharma , industrial biotech , agriculture , and med-tech fields . Dr . A . Ramkishan , Deputy Drugs Controller ( India ) at the Ministry of Health and Family Welfare , Government of India was the chief guest at the symposium . Welcoming the Chief Guest of Phase 1 symposium , Dr . Ramjee Pallela , COO at AIC – CCMB highlighted the importance of new-age research and emphasized on the use of technology to build connects between Industry , Research Institutes and Regulators .
48
BioVoiceNews | November / December 2023